Key Takeaways
- Jim Cramer cautioned investors to avoid chasing stocks with “parabolic” price action, particularly in technology and artificial intelligence
- He advocated for finding value in neglected, beaten-down equities instead of following momentum
- Cramer’s Charitable Trust accumulated Johnson & Johnson positions during the stock’s decline
- He named J&J his top pharmaceutical pick for 2026, ranking it ahead of Eli Lilly due to pipeline strength and strategic restructuring
- Cramer emphasized maintaining balanced exposure across both popular and unpopular market segments
On Monday’s broadcast, CNBC’s Mad Money host Jim Cramer delivered a contrarian message to investors: abandon the chase for market momentum darlings and focus attention on the names that have been left behind.
According to Cramer, securities exhibiting “parabolic” price trajectories—particularly those in the technology and artificial intelligence sectors—represent risky entry points. He admitted that his own attempts to ride these momentum waves have typically resulted in losses.
“Those are all too hot, hot, hot for me,” Cramer remarked when discussing high-momentum semiconductor and AI-related equities.
Rather than pursuing names like Intel or Advanced Micro Devices, Cramer revealed he’s implementing a contrary strategy. His approach centers on accumulating shares of high-quality corporations that have experienced selloffs and lost market favor.
His CNBC Investing Club Charitable Trust recently initiated purchases of Johnson & Johnson shares during the stock’s descent. The healthcare sector currently ranks as the S&P 500’s worst performer in 2025.
“We are buying it in freefall,” Cramer explained. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Rationale for Johnson & Johnson
Cramer revealed that Johnson & Johnson has displaced Eli Lilly as his preferred pharmaceutical investment. He pointed to the company’s robust drug pipeline and ongoing strategic transformation as primary catalysts for his conviction.
Johnson & Johnson has been systematically divesting slower-growth business units while intensifying its pharmaceutical research focus. The pharmaceutical giant currently has numerous compounds in advanced clinical trials alongside several recent regulatory approvals.
Cramer attributed the recent stock weakness primarily to market noise, specifically litigation concerns surrounding talc products. He believes these legal worries have obscured the substantial operational improvements occurring within the organization.
He also identified a recurring pattern surrounding Johnson & Johnson’s earnings releases. The shares frequently experience morning selloffs following results, then rebound once management’s conference call commences. “If it gets blasted, try to get some,” he advised.
Building a Balanced Portfolio Approach
Cramer’s underlying message addressed portfolio construction principles. He warned that concentrating exclusively in the market’s hottest sectors creates vulnerability when sentiment inevitably shifts.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he stated.
When specific market segments fall from grace, maintaining positions in undervalued names ensures continued portfolio performance. Cramer attributed this wisdom to lessons learned during his time at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare equities have experienced significant pressure throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading sessions amid persistent sector-wide headwinds.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
